title: [Treatment by urokinase of myocardial infarction and threatened infarction. Randomised study of 120 cases].
abstract: Two randomized series of 60 cases of myocardial infarction or menace syndrome have been treated at the acute stage, one by Heparin alone, the other by the combination Urokinase-Heparin. The average dosage was 300 mg Heparin in the first series, of 2,700,000 CTA units of Urokinase combined with 240 mg of Heparin in the second series. After the first 24 hours, equal heparinization was performed in both series up to the third week. Significantly different results were obtained in the two series. They favour Urokinase and concern: -- the disappearance time of pain, -- the course of the arrhythmias and of cardiac failure, -- the regression or limitation of the necrosis q waves and the lesion areas on the electrocardiogram. Finally the 30th-day overall mortality was 13% in the Heparin series and 3% in the myocardial infarction on the way of constitution, or which have done so for less than 24 hours.
mesh_terms: D000328:Adult; D000368:Aged; D001145:Arrhythmias, Cardiac / Q000209:etiology; D002588:Cesium Radioisotopes; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D010450:Endopeptidases / Q000627:therapeutic use*; D005260:Female; D005342:Fibrinolysis; D006333:Heart Failure / Q000209:etiology; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D009203:Myocardial Infarction / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D009336:Necrosis; D010146:Pain / Q000188:drug therapy; D011877:Radionuclide Imaging; D012075:Remission, Spontaneous; D012737:Sex Factors; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use*
chemical_list: D002588:Cesium Radioisotopes; D006493:Heparin; D010450:Endopeptidases; D014568:Urokinase-Type Plasminogen Activator
vernacular_title: Le traitement par l'urokinase des infarctus du myocarde et syndromes de menace. Etude randomisée de 120 cas]